								
			TM6 Recd PCT/PTO 18 DEC 2002					
FORM (REV)	PTO-139 11-2000)	90 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER					
	TI	RANSMITTAL LETTER TO THE UNITED STATES	GKS-101.0 (7911/83687)					
		DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR.					
		CONCERNING A FILING UNDER 35 U.S.C. 371	09/936,852					
INTE		TONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED					
TITI		PCT/EP00/02410 03/17/2000 NVENTION	03/17/1999					
		LEIC ACID MOLECULE COMPRISING A NUCLEIC ACID COL	DING FOR A HEMOCYANIN					
		T(S) FOR DO/EO/US						
Ju	rgen	MARKL, et al.						
		The state of the s						
		herewith submits to the United States Designated/Elected Office (DO/EO/US)						
1.		This is a FIRST submission of items concerning a filing under 35 U.S.C. 37						
2.	×	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3.	×	This is an express request to begin national examination procedures (35 U.S. (9) and (24) indicated below.	C. 371(f)). The submission must include itens (5), (6),					
4.		The US has been elected by the expiration of 19 months from the priority date (Article 31).						
5.		A copy of the International Application as filed (35 U.S.C. 371 (c) (2))						
		a. is attached hereto (required only if not communicated by the Interr	national Bureau).					
		b. has been communicated by the International Bureau.						
		c. is not required, as the application was filed in the United States Rec	ceiving Office (RO/US).					
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
		 a. is attached hereto. 						
		 b. has been previously submitted under 35 U.S.C. 154(d)(4). 						
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))						
		a. are attached hereto (required only if not communicated by the Inter-	national Bureau).					
		 b. have been communicated by the International Bureau. 						
		c. have not been made; however, the time limit for making such amen	dments has NOT expired.					
		 d. have not been made and will not be made. 						
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).						
10.		An English language translation of the annexes to the International Prelimina Article 36 (35 U.S.C. 371 (c)(5)).	ary Examination Report under PCT					
11.		A copy of the International Preliminary Examination Report (PCT/IPEA/409	9).					
12.		A copy of the International Search Report (PCT/ISA/210).						
I	tems 1	3 to 20 below concern document(s) or information included:						
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
15.		A FIRST preliminary amendment.						
16.		A SECOND or SUBSEQUENT preliminary amendment.						
17.		A substitute specification.						
18.		A change of power of attorney and/or address letter.						
19.	\boxtimes	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.						
20.		A second copy of the published international application under 35 U.S.C. 154(d)(4).						
21.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).						
22.	\boxtimes	Certificate of Mailing by Express Mail						
22	IX1	Other items or information:						

Copy of Notification of Defective Response (2pgs); Copy of Raw Sequence Listing Error Report (9 pgs); Paper Copy of Substitute Sequence Listing (84 pgs); Disketile with CRF of Sequence Listing; Amendment under 37 CFR §1.825 (4pgs); Certificate of Express Mailing and Postcard

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/936,852				NTERNATIONAL APPLICATION NO. PCT/EP00/02410					ATTORNEY'S DOCKET NUMBER GKS-101.0 (7911/83687)		
24. The following fees are submitted:.							CALCULATIONS PTO USE ONLY				
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO						10.00					
							l				
							1				
	☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)										
	CC120.	ENTER APPROPRI		E AM				\$0.00			
months	from the ear	0 for furnishing the oath or decla liest claimed priority date (37 CI	FR 1.492 (e)).					\$0.00			
CL/ Total ci	AIMS	NUMBER FILED	NUMBER EXT	RA	x \$18.0		 	\$0.00			
	ndent claims	- 3 =	0					\$0.00			
		Dependent Claims (check if applicable).						\$0.00			
			ABOVE CALC			=		\$0.00			
□ A	 Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2. 							\$0.00			
				SUB	TOTAL	=		\$0.00			
Process months	sing fee of \$1 from the ear	30.00 for furnishing the English liest claimed priority date (37 CI	translation later than FR 1.492 (f)).	□ 20	0 🗆 3	0 +		\$0.00			
<u> </u>			TOTAL NAT	IONAI	L FEE	=		\$0.00			
Fee for	recording the	e enclosed assignment (37 CFR 1 appropriate cover sheet (37 CFR	.21(h)). The assignme 3.28, 3.31) (check if	ent must b			\$0.00				
				ENCLOSED =				\$0.00			
1						Amoun refu		S			
L							ch:	arged	s		
a.											
þ.	b. Please charge my Deposit Account No. in the amount of to cover the above fees. A duplicate copy of this sheet is enclosed.										
c.	c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0920 A duplicate copy of this sheet is enclosed.										
d.											
NOTE: 1.137(a	NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
SEND	ALL CORRI		Sa Alelado								
	Attn: Shannon L. Nebolsky Welsh & Katz, Ltd.				SIGNATURE						
120 S.	Riverside P	Shannon L. Nebolsky									
Chicago, IL 60606-3912					NAME						
LA DER AND					41,217						
ı			REGISTRATION NUMBER								
l		24628		December 18, 2002							
24028 PATENT , TRADEMARK OFFICE					DATE						
į.				i							

IN THE UNITED STATES DESIGNATED OFFICE/ELECTED OFFICE (DO/EO/US) OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Jurgen MARKL)	Attorney Docket No.:
)	7911/83687
U.S. Serial No.: 09/936,852)	GKS-101.0
Confirmation No.: 1442)	
)	DO/EO/US Examiner:
Filed under 35 U.S.C. 371 11/28/2001)	Shelby J. Vigil
From Int'l Ser. No.: PCT/ES01/00079)	
Int'l Filing Date: March 2, 2001)	Group Art Unit:
Priority Date: March 17, 1999)	not yet assigned
-)	
Title: NUCLEIC ACID MOLECULE)	
COMPRISING A NUCLEIC ACID)	
CODING FOR A HEMOCYANIN)	

AMENDMENT UNDER 37 C.F.R. § 1.825 INCLUDING STATEMENTS UNDER 37 CFR § 1.821 and § 1.825

Commissioner for Patents U.S. Patent and Trademark Office Box SEQUENCE P.O. Box 2327 Arlington, VA 22002

Sir:

This paper is a Response to the Notification of Defective Response that was mailed November 18, 2002, together with a Raw Sequence Listing Error Report (copies of both are enclosed herewith), regarding the response to the Notice of Missing Requirements under 35 U.S.C. § 371 that was filed July 3, 2002 in the United States Designated/Elected Office (DO/EO/US).

The Raw Sequence Listing Error Report was based upon the new electronic copy of the Sequence Listing that was filed with that response on July 3, 2002.

Enclosed herewith is a corrected copy of the Sequence Listing, in both Paper and Computer Readable Form. The Paper copy is a page numbered version of the enclosed CRF, formatted for A4 paper. Please substitute the present paper copy of the Sequence Listing into the specification. The present paper copy is substantively identical to that filed with the original patent application papers on September 17, 2001, and is thus already part of the Specification. Pursuant to 37 C.F.R. § 1.825(a), it is hereby stated that no new matter is introduced via this amendment.

Furthermore, pursuant to 37 C.F.R. § 1.821(h), it is hereby stated that the enclosed submission does not include matter which goes beyond the disclosure in the international application as filed.

Please substitute the enclosed Computer-Readable form of the Sequence Listing into the patent file, as required by 37 U.S.C. § 1.821(e). The file on the CRF is MS-DOS text with line breaks (*.txt) format from Microsoft Word 2000 based on the ASCII output from PatentIn version 2.1, created 03/02/2001 in PatentIn version 2.1 on a Windows 95/PC compatible computer, as modified on 12/18/2002. The Sequence Listing file, "936852.txt" was copied onto the enclosed diskette 12/18/2002.

Pursuant to 37 C.F.R. § 1.821(f), it is hereby stated that the sequence listing information recorded in computer readable form is identical to the written (on paper) Sequence Listing.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Shannon L. Nebolsky, Reg. No. 1,21

Enclosures

Transmittal Letter

Copy of the Notification of Defective Response Copy of the Raw Sequence Listing Error Report

Paper Copy of Sequence Listing

Computer Readable Diskette

U.S. Ser. No. 09/936,852 - Jürgen MARKL

U.S. PTO Customer No. 24628 WELSH & KATZ, LTD. 120 South Riverside Plaza, 22nd Floor Chicago, Illinois 60606 Phone (312) 655-1500 Fax No. (312) 655-1501

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this Amendment under 37 C.F.R. § 1.825 including Statements under 37 C.F.R. § 1.821 and § 1.825, together with a substitute Sequence Listing (paper and CRF), Transmittal Letter and its stated enclosures, are being deposited with the United States Postal Service as Express Mail Label No. EV 045460775 US, postage prepaid, in an envelope addressed to: Commissioner for Patents, Box SEQUENCE, P.O. Box 2327, Arlington, VA 22202 on December 18, 2002.

Shannon L. Nebolsky